
A Canadian clinical trial led by researchers at the University of Calgary’s Hotchkiss Brain Institute (HBI), at the Cumming School of Medicine (CSM), shows that minocycline, a common acne medication, can slow the progress of relapsing-remitting multiple sclerosis (MS) in people who have recently experienced their first symptoms.
In addition to being an unexpected discovery — an acne drug benefitting a neurological disorder — the discovery is significant as it offers a safe and affordable treatment option for those with early onset MS. This discovery could impact thousands of newly diagnosed MS patients around the world. Continue reading